Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Clin Oncol ; 18(1): 12-7, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10623688

RESUMEN

PURPOSE: To study the effectiveness of combined systemic chemotherapy and local ophthalmic therapy for retinoblastoma with the goal of avoiding enucleation and external-beam radiation therapy (EBRT). PATIENTS AND METHODS: This was a prospective, nonrandomized, single-arm clinical trial. Seventy-five eyes were followed in 47 children. Patients were treated with a six-cycle protocol of vincristine, etoposide, and carboplatin. Most (83%) also received ophthalmic treatment (cryotherapy, laser photocoagulation, thermotherapy, or plaque radiation therapy) during and/or after the chemotherapy. RESULTS: With a median follow-up of 13 months, event-free survival was 74%, with an event defined as enucleation and/or EBRT. Six children required EBRT in seven eyes (9%); five required enucleation of one eye (7%); five required a combination of EBRT and enucleation in six eyes (8%). Reese-Ellsworth groups 1, 2, and 3 eyes had excellent results, with avoidance of EBRT or enucleation in all 39. Treatment of groups 4 and 5 was less successful, with 33% of six eyes and 53% of 30 eyes, respectively, requiring EBRT and/or enucleation. Toxicities from chemotherapy were mild and included cytopenias (89%), fever and neutropenia (28%), infection (9%), and gastrointestinal symptoms, dehydration, and vincristine neurotoxicity (40%). No patients developed a second malignancy, metastatic disease, renal disease, or ototoxicity. CONCLUSION: In retinoblastoma patients with Reese-Ellsworth eye groups 1, 2, or 3, systemic chemotherapy used with local ophthalmic therapies can eliminate the need for enucleation or EBRT without significant systemic toxicity. More effective therapy is required for Reese-Ellsworth eye groups 4 and 5.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Carboplatino/administración & dosificación , Niño , Preescolar , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Estudios Prospectivos , Neoplasias de la Retina/terapia , Retinoblastoma/terapia , Vincristina/administración & dosificación
2.
Arch Ophthalmol ; 116(12): 1613-7, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9869790

RESUMEN

OBJECTIVE: To determine the outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. METHODS: Prospective analysis of 27 eyes in 22 patients with group V retinoblastoma treated with either 2- or 6-cycle chemoreduction and focal treatment methods (argon laser photocoagulation, transpupillary thermotherapy, cryotherapy, and plaque radiotherapy). The need for external beam irradiation and the eventual globe salvage rate were assessed. Median follow-up was 28 months. RESULTS: There were 16 eyes in the 2-cycle chemoreduction treatment group and 11 eyes in the 6-cycle chemoreduction treatment group. No significant difference was noted between the 2 groups with respect to baseline patient and eye findings. After chemoreduction treatment, external beam irradiation was necessary in 12 (75%) of 16 eyes in the 2-cycle chemoreduction treatment group and in 4 (36%) of 11 eyes in the 6-cycle chemoreduction treatment group. There was no statistical difference between the 2- and 6-cycle chemoreduction treatment groups with respect to necessity for external beam irradiation (logistic regression analysis). All 4 eyes in the 2-cycle chemoreduction treatment group and 3 of 12 eyes in the 2-cycle chemoreduction treatment and irradiation group were eventually enucleated, the globe salvage rates being 0% and 75%, respectively. Two of 7 eyes in the 6-cycle chemoreduction treatment group and 1 of 4 eyes in the 6-cycle chemoreduction treatment and irradiation group were enucleated, the globe salvage rates being 71% and 75%, respectively. Except for the 2-cycle chemoreduction treatment group, in which the globe salvage rate was significantly lower (P = .03), there was no difference among the other 3 groups (2-cycle chemoreduction treatment and irradiation, 6-cycle chemoreduction treatment, and 6-cycle chemoreduction treatment and irradiation) with respect to globe salvage (logistic regression analysis). CONCLUSIONS: Local tumor control of group V retinoblastoma is possible with 6-cycle chemoreduction and focal therapy when external beam irradiation is not used. A larger sample size is necessary to determine how often external beam irradiation can be avoided.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Braquiterapia , Carboplatino/administración & dosificación , Preescolar , Criocirugía , Esquema de Medicación , Etopósido/administración & dosificación , Enucleación del Ojo , Femenino , Estudios de Seguimiento , Humanos , Hipertermia Inducida , Lactante , Coagulación con Láser , Masculino , Estudios Prospectivos , Neoplasias de la Retina/clasificación , Neoplasias de la Retina/patología , Retinoblastoma/clasificación , Retinoblastoma/patología , Resultado del Tratamiento , Vincristina/administración & dosificación
3.
Ophthalmology ; 104(12): 2101-11, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9400771

RESUMEN

OBJECTIVE: The purpose of the study is to investigate chemoreduction and adjuvant treatment (AT) for retinoblastoma and its effect on complete retinal tumor control, vitreous seed control, and subretinal seed control. DESIGN: The study design was a prospective, nonrandomized clinical trial. PARTICIPANTS: There were 130 intraocular retinoblastomas in 52 eyes of 32 consecutive patients observed for at least 1 year after initiation of treatment. INTERVENTION: Treatment with chemoreduction using vincristine, etoposide, and carboplatin (VEC) and adjuvant treatment (+ AT) (cryotherapy, laser photocoagulation, thermotherapy, chemothermotherapy, plaque radiation therapy, or external beam radiation therapy) were assessed. MAIN OUTCOME MEASURES: The effect of chemoreduction for 6 cycles (VEC x 6) versus fewer than 6 cycles (VEC x <6) on retinoblastoma control was analyzed. Furthermore, the impact of adjuvant treatment (+ AT) versus no adjuvant treatment (no AT) on retinoblastoma control was analyzed. RESULTS: Retinal tumors showed favorable initial regression with chemoreduction. Adjuvant treatment was applied to 93% of the retinal tumors after chemoreduction and only 2% recurred over the mean follow-up of 17 months (range 13-27 months). Vitreous seeds and subretinal seeds showed initial regression and often complete disappearance with chemoreduction. In those eyes with seeds before treatment, the addition of AT to VEC for 6 cycles decreased the vitreous seed recurrence from 75% to 0% (P = 0.04) and also decreased the subretinal seed recurrence from 67% to 0% (P = 0.003). More important, when considering that enucleation or external beam radiation therapy was the only other treatment option for these 52 eyes, the authors were successful in avoiding these methods in 42% of cases. Of the 36 eyes classified as Reese-Ellsworth group 5, there was 78% ocular salvage, and external beam radiation therapy was avoided in 25% of these eyes. There was a 100% ocular salvage in the group 5 eyes that received VEC for 6 cycles + AT to retinal tumors and seeds. CONCLUSIONS: Chemoreduction and AT to intraocular retinoblastoma and its seeds provides good retinal tumor control, even in eyes with advanced disease. Chemoreduction alone generally is not adequate to achieve complete tumor seed control. Cautious follow-up of affected patients is recommended because the risk for recurrent vitreous and subretinal seeds is substantial and proper treatment is critical for salvaging the eye.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Siembra Neoplásica , Neoplasias de la Retina/tratamiento farmacológico , Retinoblastoma/tratamiento farmacológico , Carboplatino/administración & dosificación , Preescolar , Terapia Combinada , Etopósido/administración & dosificación , Oftalmopatías/tratamiento farmacológico , Enucleación del Ojo , Femenino , Humanos , Lactante , Masculino , Recurrencia Local de Neoplasia , Estudios Prospectivos , Neoplasias de la Retina/radioterapia , Neoplasias de la Retina/cirugía , Retinoblastoma/radioterapia , Retinoblastoma/cirugía , Vincristina/administración & dosificación , Cuerpo Vítreo/efectos de los fármacos
5.
Neurology ; 46(6): 1669-73, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8649567

RESUMEN

We report three patients with gangliogliomas involving the optic chiasm via distinct mechanisms. The ganglioglioma in one patient likely originated in the temporal lobe and spread medially to involve the chiasm, and diffuse spinal cord dissemination also occurred. Chiasmal involvement in this manner and dissemination at presentation are unusual for gangliogliomas. The tumor in a second patient was intrinsic to the hypothalmus and chiasm, while in the third patient, it involved both optic tracts, and a cyst compressed the chiasm laterally. Two patients developed severe bilateral visual loss, while the other had a stable bitemporal hemianopsia. Two patients received radiotherapy, but one continued to lose vision. Although gangliogliomas rarely involve chiasm, the mechanisms by which they produce chiasmal visual loss may be diverse, and the long-term visual prognosis is variable.


Asunto(s)
Neoplasias de los Nervios Craneales , Ganglioglioma , Síndromes de Compresión Nerviosa/etiología , Quiasma Óptico/patología , Adolescente , Adulto , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Niño , Terapia Combinada , Neoplasias de los Nervios Craneales/complicaciones , Neoplasias de los Nervios Craneales/diagnóstico , Neoplasias de los Nervios Craneales/patología , Neoplasias de los Nervios Craneales/terapia , Quistes/complicaciones , Etopósido/uso terapéutico , Femenino , Ganglioglioma/complicaciones , Ganglioglioma/diagnóstico , Ganglioglioma/patología , Ganglioglioma/terapia , Cefalea/etiología , Humanos , Hipotálamo/patología , Imagen por Resonancia Magnética , Masculino , Trastornos Mentales/etiología , Invasividad Neoplásica , Síndromes de Compresión Nerviosa/cirugía , Neoplasias de la Médula Espinal/diagnóstico , Neoplasias de la Médula Espinal/patología , Neoplasias de la Médula Espinal/terapia , Espacio Subaracnoideo , Lóbulo Temporal/patología , Derivación Ventriculoperitoneal , Trastornos de la Visión/etiología , Agudeza Visual
6.
Am J Clin Nutr ; 39(3): 410-5, 1984 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-6695840

RESUMEN

A granulocyte fraction, composed primarily of polymorphonuclear neutrophils, was harvested from six male and six female chronic hemodialysis patients receiving folate as their sole vitamin supplement. Cells were assayed for water soluble vitamins and levels compared with cells from 12 age- and sex-matched controls. Thiamin, riboflavin, and vitamin B6 and B12 levels were not significantly different from controls. In contrast, pantothenate and biotin were significantly increased while ascorbate and nicotinate were significantly reduced in dialysis patients. Neutrophil folylmonoglutamates were significantly increased in chronic hemodialysis patients, but after conjugase treatment no significant difference was observed. The erythrocytes and plasma from these two groups were also compared. In the erythrocytes of chronic hemodialysis patients, no vitamin deficiencies were observed. Significantly elevated levels of vitamin B12, riboflavin, biotin, and pantothenate were present in the patients, while thiamin, vitamin B6, nicotinate, and ascorbate were not significantly different from controls. In plasma, only ascorbate was significantly decreased in the patient group; biotin, riboflavin, and pantothenate were elevated. No significant difference was observed for vitamins B6, B12, and thiamin.


Asunto(s)
Eritrocitos/metabolismo , Granulocitos/metabolismo , Fallo Renal Crónico/sangre , Diálisis Renal , Vitaminas/sangre , Adulto , Avitaminosis/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Plasma/metabolismo , Solubilidad , Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA